KAI-1678

N/A

Report date: 2022/11/25 18:08:14
NME

Base Information

Drug NameKAI-1678
Drug Alias NameKAI-1678
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionProtein kinase C zeta inhibitors
TargetsProtein kinase C zeta
Therapy Area/IndicationsPain, PostoperativeNeuralgia, PostherpeticSpinal Cord Injuries
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustralia
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKai Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPain, PostoperativeNeuralgia, PostherpeticSpinal Cord Injuries

Other Information

ATC CodeN/A
Related LinksN/A